Equillium (EQ) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
1 Jun, 2026Mechanistic insights into AhR and miR-124 axis
AhR is a ligand-activated transcription factor involved in detoxification, immune modulation, anti-inflammatory cytokine production, antioxidant protein expression, and barrier repair, with responses varying by ligand and cell type.
AhR activation induces both genomic and non-genomic pathways, including immune regulation and barrier function, with regulatory microRNAs such as miR-124 being key downstream effectors.
miR-124 is induced downstream of AhR activation in immune cells, but not in epithelial cells, and acts as a negative regulator of AhR; overexpression decreases AhR and promotes inflammation, while inhibition increases AhR and reduces inflammation.
Dietary AhR ligands favor immune regulation and barrier repair, while xenobiotics drive detoxification pathways.
AhR antagonism blocks induction of miR-124, CYP1A1, IL-10, and IL-22, highlighting pathway dependency and the centrality of AhR signaling in immune and epithelial homeostasis.
ABX464 and EQ504 as AhR modulators
ABX464 is a moderately potent AhR modulator binding the PAS-B domain, while its glucuronidated form (ABX464-N-Glu) does not bind or modulate AhR.
Pharmacophore and docking analyses show ABX464 shares structural features with other AhR modulators and docks into the PAS-B pocket via conserved π-π stacking.
EQ504 and ABX464 are confirmed AhR modulators that induce miR-124 and anti-inflammatory cytokines, with EQ504 designed for high colon tissue and low systemic exposure.
AhR antagonism with GNF-351 blocks ABX464-induced AhR activation, confirming direct, on-target activity.
Functional and translational findings
ABX464 and EQ504 induce miR-124 and suppress pro-inflammatory cytokines (IL-6, IL-17, TNF-α, IL-23, IL-12, IL-1β) in PBMCs, CD4+ T cells, and M1 macrophages in an AhR-dependent manner.
Both compounds reduce IL-17a+ cells in CD4+ T cells and inhibit IL-6, TNFα, IL-23, IL-12, and IL-1β in M1 macrophages.
EQ504, but not ABX464, significantly induces anti-inflammatory IL-22 in PBMCs.
In regulatory T cells and M2 macrophages, ABX464 and EQ504 induce CYP1A1, miR-124, IL-10, and IL-22 in an AhR-dependent manner; antagonism blocks these effects.
Both compounds decrease AhR expression in regulatory T cells and enhance wound healing and barrier integrity in intestinal epithelial cells via AhR activation.
Latest events from Equillium
- EQ504, a novel AhR modulator for ulcerative colitis, enters Phase I in mid-2026 after $50M financing.EQ
Cantor Global Healthcare Conference 20258 Jul 2026 - EQ504 targets UC with a novel, colon-specific approach, aiming for improved remission and safety.EQ
Corporate presentation14 May 2026 - Q1 2026 net loss narrowed, cash runway into 2029, Phase 1 EQ504 study set for mid-2026.EQ
Q1 202613 May 2026 - Key votes include director elections, reverse split, share increase, and auditor ratification.EQ
Proxy filing15 Apr 2026 - Annual meeting to vote on directors, reverse split, auditor, and share increase; Board recommends approval.EQ
Proxy filing15 Apr 2026 - 18.9M shares registered for resale after $35M private placement; pipeline targets autoimmune diseases.EQ
Registration filing7 Apr 2026 - Shareholders will vote on director elections, reverse stock split, auditor ratification, and share authorization.EQ
Proxy filing30 Mar 2026 - EQ504 targets UC with a novel, validated approach and is fully funded through key milestones.EQ
Corporate presentation30 Mar 2026 - EQ504 clinical trials set for 2026, $85M raised, cash runway into 2029, no 2025 revenue.EQ
Q4 202525 Mar 2026